' Call for paper

Call for Paper (WBP-2026)

The Organising Committee cordially invites researchers, academicians, industry experts, clinical scientists, regulatory professionals, and students from across the globe to submit original research contributions, review articles, and technical case studies to the 1st International Conference on the World of Biopharmaceuticals (WBP-2026). WBP-2026 serves as a global multidisciplinary platform for presenting cutting-edge developments, innovative technologies, and strategic breakthroughs across the full continuum of pharmaceutical and biopharmaceutical sciences.

Key Themes & Disciplines:
  • Pharmaceutics & Novel Drug Delivery Systems (NDDS): nanomedicine, liposomes, lipid nanoparticles (LNPs), controlled/sustained release formulations, targeted delivery, and targeted bio-drug delivery platforms.
  • Pharmaceutical Chemistry & Drug Discovery: medicinal chemistry, computer-aided drug design (CADD), rational drug design, natural product chemistry, molecular modeling, and lead optimization.
  • Pharmacology & Toxicology: preclinical studies, safety pharmacology, immunotoxicity, clinical trial design, pharmacokinetics and pharmacodynamics (PK/PD), and biomarker development.
  • Pharmaceutical Analysis & Quality Assurance: method development and validation, bioanalysis, high-throughput screening, stability testing, host cell protein (HCP) analysis, and Quality by Design (QbD).
  • AI & Digital Health in Pharma: machine learning in molecular design, digital twins for bioprocess optimization, predictive modeling, big data analytics, and automated high-throughput screening.
  • Industrial Pharmacy & Bioprocessing: upstream/downstream processing, continuous biomanufacturing, single-use technologies, formulation stability, and scale-up engineering.
  • Pharmacognosy & Phytopharmaceuticals: herbal drug standardization, bioactive isolation, traditional medicine integration, and green synthesis of pharmaceuticals.
  • Biologics & Advanced Therapies: monoclonal antibodies, biosimilars, recombinant proteins, antibody-drug conjugates (ADCs), cell and gene therapies (CAR-T, CRISPR), and mRNA technology.
  • Regulatory Affairs, Intellectual Property & Supply Chain: global regulatory harmonization, FDA/EMA submission strategies, patent law, bio-ethics, cold-chain logistics, and pharmacovigilance.